Modality
mRNA
MOA
PCSK9i
Target
IL-13
Pathway
Neuroinflam
MelanomaOvarian Ca
Development Pipeline
Preclinical
~Oct 2014
→ ~Jan 2016
Phase 1
~Apr 2016
→ ~Jul 2017
Phase 2
Oct 2017
→ Aug 2030
Phase 2Current
NCT04847841
470 pts·Melanoma
2017-10→2028-03·Not yet recruiting
NCT03274516
1,907 pts·Ovarian Ca
2024-11→2030-08·Completed
2,377 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-03-212.0y awayPh2 Data· Melanoma
2030-08-034.3y awayPh2 Data· Ovarian Ca
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2
Not yet…
P2
Complet…
Catalysts
Ph2 Data
2028-03-21 · 2.0y away
Melanoma
Ph2 Data
2030-08-03 · 4.3y away
Ovarian Ca
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04847841 | Phase 2 | Melanoma | Not yet recr... | 470 | ORR |
| NCT03274516 | Phase 2 | Ovarian Ca | Completed | 1907 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| MRN-7601 | Moderna | Phase 2 | IL-13 |